Suppr超能文献

mLST8 表达增强与肝细胞癌的肿瘤进展相关。

Enhanced mLST8 Expression Correlates with Tumor Progression in Hepatocellular Carcinoma.

机构信息

Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.

Shanghai Institute of Liver Disease, Shanghai, China.

出版信息

Ann Surg Oncol. 2020 May;27(5):1546-1557. doi: 10.1245/s10434-020-08263-6. Epub 2020 Mar 10.

Abstract

BACKGROUND

The mechanistic target of rapamycin (mTOR) pathway, containing mTOR complex 1 (mTORC1) and mTORC2, is dysregulated in multiple cancers, including hepatocellular carcinoma (HCC). Mammalian lethal with sec-13 protein 8 (mLST8) is a shared constituent of both mTORC1 and mTORC2, yet little is known regarding its role in HCC development.

METHODS

mLST8 expression was detected in a total of 186 pairs of HCC and adjacent non-tumor specimens. The correlation between mLST8 level and clinicopathological features or prognostic significance were analyzed. The role of mLST8 on biological functions was also preliminarily studied.

RESULTS

The study revealed that the mLST8 level was dramatically higher in HCC specimens than in adjacent non-tumor specimens. mLST8 overexpression positively correlated with tumor size, differentiation, and vessel invasion. Cases with elevated mLST8 level had more unfavorable overall survival (OS) and disease-free survival (DFS) than those with downregulated mLST8 level. Multivariate analysis demonstrated that mLST8 upregulation was an independent predictive marker for OS and DFS. Calibration curves from nomogram models indicated an excellent coherence between nomogram prediction and actual situation. Decision curve analysis proved that mLST8-based nomograms presented much higher predictive accuracy when compared with conventional clinical staging systems. Mechanistically, mLST8 enhanced cell proliferation and invasion through the AKT (protein kinase B) pathway.

CONCLUSIONS

Our study demonstrates that mLST8 exerts an oncogenic role in HCC and may become a promising prognostic biomarker and therapeutic target for HCC patients.

摘要

背景

雷帕霉素靶蛋白(mTOR)通路,包含 mTOR 复合物 1(mTORC1)和 mTORC2,在多种癌症中失调,包括肝细胞癌(HCC)。哺乳动物致死性 SEC13 蛋白 8(mLST8)是 mTORC1 和 mTORC2 的共同组成部分,但关于其在 HCC 发展中的作用知之甚少。

方法

在总共 186 对 HCC 和相邻非肿瘤标本中检测了 mLST8 的表达。分析了 mLST8 水平与临床病理特征或预后意义的相关性。还初步研究了 mLST8 在生物学功能上的作用。

结果

研究表明,HCC 标本中的 mLST8 水平明显高于相邻非肿瘤标本。mLST8 过表达与肿瘤大小、分化和血管侵犯呈正相关。mLST8 水平升高的病例总生存(OS)和无病生存(DFS)较 mLST8 水平降低的病例更差。多变量分析表明,mLST8 上调是 OS 和 DFS 的独立预测标志物。列线图模型的校准曲线表明,列线图预测与实际情况之间具有极好的一致性。决策曲线分析证明,与传统临床分期系统相比,基于 mLST8 的列线图具有更高的预测准确性。机制上,mLST8 通过 AKT(蛋白激酶 B)通路增强细胞增殖和侵袭。

结论

我们的研究表明,mLST8 在 HCC 中发挥致癌作用,可能成为 HCC 患者有前途的预后生物标志物和治疗靶点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验